Orchard Therapeutics (ORTX) Stock Price, News & Analysis

Company Overview

Orchard Therapeutics, a Kyowa Kirin company, is a global gene therapy leader focused on ending the devastation caused by genetic and other severe diseases by discovering, developing, and commercializing new treatments that tap into the curative potential of hematopoietic stem cell (HSC) gene therapy. In this approach, a patient’s own blood stem cells are genetically modified outside of the body and then reinserted, with the goal of correcting the underlying cause of disease with a single treatment.

Founded in 2015, Orchard’s roots go back to some of the first research and clinical developments involving HSC gene therapy. Our team has played a central role in the evolution of this technology from a promising scientific idea to a potentially life-transforming reality. Today, Orchard is advancing a pipeline of HSC gene therapies designed to address serious diseases where the burden is immense for patients, families and society and current treatment options are limited or do not exist.

Written by Jeffrey Neal Johnson

Key Stats

• Today's Range: $16.70 to $16.70
• 50-Day Range: $16.40 to $16.70
• 52-Week Range: $4.24 to $16.72
• Volume: N/A
• Average Volume: 157,287 shs
• Market Capitalization: $380.09 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

ORTX Stock Analysis - Frequently Asked Questions

How were Orchard Therapeutics' earnings last quarter?

Orchard Therapeutics plc (NASDAQ:ORTX) announced its earnings results on Monday, May, 15th. The company reported ($0.12) EPS for the quarter, beating analysts' consensus estimates of ($1.61) by $1.49. The business earned $1.24 million during the quarter, compared to analysts' expectations of $6.48 million. Orchard Therapeutics had a negative net margin of 333.90% and a negative trailing twelve-month return on equity of 74.94%.

When did Orchard Therapeutics' stock split?

Orchard Therapeutics's stock reverse split before market open on Friday, March 10th 2023. The 1-10 reverse split was announced on Friday, March 10th 2023. The number of shares owned by shareholders was adjusted after the market closes on Friday, March 10th 2023. An investor that had 100 shares of stock prior to the reverse split would have 10 shares after the split.

When did Orchard Therapeutics IPO?

Orchard Therapeutics (ORTX) raised $200 million in an IPO on Wednesday, October 31st 2018. The company issued 13,300,000 shares at a price of $14.00-$16.00 per share. J.P. Morgan, Goldman Sachs and Cowen acted as the underwriters for the IPO and Wedbush PacGrow was co-manager.

What other stocks do shareholders of Orchard Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Orchard Therapeutics investors own include NVIDIA (NVDA), Broadcom (AVGO), Meta Platforms (META), Arista Networks (ANET), Adobe (ADBE), Jabil (JBL) and e.l.f. Beauty (ELF).

Company Calendar

• Last Earnings: 5/15/2023
• Today: 3/13/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: Biotechnology
• Sub-Industry: N/A
• Current Symbol: NASDAQ:ORTX
• Previous Symbol: NASDAQ:ORTX
• CIK: 1748907
• Web: www.orchard-tx.com
• Phone: 442038088286
• Fax: N/A
• Employees: 166
• Year Founded: N/A

Profitability

• EPS (Most Recent Fiscal Year): ($0.94)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: $-150,660,000.00
• Net Margins: -333.90%
• Pretax Margin: -334.54%
• Return on Equity: -74.94%
• Return on Assets: -33.51%

Debt

• Debt-to-Equity Ratio: 0.20
• Current Ratio: 3.12
• Quick Ratio: 2.98

Sales & Book Value

• Annual Sales: $22.66 million
• Price / Sales: 16.77
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $7.74 per share
• Price / Book: 2.16

Miscellaneous

• Outstanding Shares: 22,760,000
• Free Float: 22,099,000
• Market Cap: $380.09 million
• Optionable: Optionable
• Beta: 0.55